Oligonucleotide degradation contributes to resistance to antisense compounds

A. Ryte, S. Morelli, M. Mazzei, A. Alama, P. Franco, G. F. Canti, A. Nicolin

Research output: Contribution to journalArticle

Abstract

A subline of the human B cell lymphoma DHL-4, grown in the artificial serum-free medium HB101, displayed a resistant phenotype to the activity of an antisense oligodeoxynucleotide (aODN) effective on the parental DHL-4 line. It was found that the cellular uptake of the 18mer aODN in the two cell lines was almost the same. In contrast, the unresponsive subline DHL-4r degraded the aODN very efficiently, in contrast to the stability of aODN inside cells of the parental DHL-4 line. Activation of the degrading 'machinery' combined with selective properties of the artificial medium may be responsible for the loss of responsiveness to aODN.

Original languageEnglish
Pages (from-to)197-200
Number of pages4
JournalAnti-Cancer Drugs
Volume4
Issue number2
Publication statusPublished - 1993

Keywords

  • antisense oligodeoxynucleotides
  • cellular uptake
  • resistant cells
  • stability

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Oligonucleotide degradation contributes to resistance to antisense compounds'. Together they form a unique fingerprint.

  • Cite this

    Ryte, A., Morelli, S., Mazzei, M., Alama, A., Franco, P., Canti, G. F., & Nicolin, A. (1993). Oligonucleotide degradation contributes to resistance to antisense compounds. Anti-Cancer Drugs, 4(2), 197-200.